article thumbnail

Will enterprises soon keep their best gen AI use cases under wraps?

CIO

Normally, a CCO develops ideas about what the market needs and communicates them to a design team, which produces sketches to then be reviewed by the CCO. As the technology exhausts its honeymoon period, and companies in all industries find new ways of using it to get ahead of the competition, a new race is on.

article thumbnail

How the new AI executive order stacks up: B-

CIO

As other recent technology waves have taught us, developments will simply come too fast for such an approach and will be driven by the speed of private industry. It is a very powerful technology, and while it is not inherently good or bad, given its sheer power, guardrails must be put into place. AI must be regulated.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Nanome raises $3 million to help scientists get up close with molecular structures in VR

TechCrunch

Part of that comes from the need to closely examine every relevant molecule, studying its chemical composition and interactions as well as its physical structure at the atomic level. Discovery and research of new molecular compounds is an expensive business, with development costs exceeding $10 billion per substance in some cases.

VR 278
article thumbnail

Funding Is Still Flowing Strong To Water-Focused Startups

Crunchbase News

Funding to startups working on water purification- and conservation-related technologies has not dried up in recent quarters, even amid a broad global contraction in venture investment. Groundwater supplies worldwide are under serious threat due to population growth, industrial development, overuse, climate change and poor water management.

article thumbnail

Postponing Elective Surgeries due to COVID-19 Might Have Pushed the Opioid Crisis to the Next Level

Battery Ventures

Patients need support to ensure that circumstances beyond their control don’t send them down the path to a lifelong struggle with chemical dependency. Adnan Asar is CEO of Lucid Lane*, founding chief technology officer of Livongo, and former global head of technology at Shutterfly. This article first appeared on Forbes.

article thumbnail

Y Combinator’s biotech startups incubate a new generation of therapies and tools

TechCrunch

These tools can essentially “code” a molecule so that it reliably sticks to a specific substance or cell type, which allows a variety of follow-up actions to be taken. For instance, a DNA machine could lock onto COVID-19 viruses and then release a chemical signal indicating infection before killing the virus.

Biotech 248
article thumbnail

Psychedelics startups are on a long journey to consumer markets, but these 5 VCs are taking the ride

TechCrunch

Additionally, the IP around these opportunities will be far more defensible, as they will be new chemical entities (NCEs). Research on psychedelics was stalled for decades due to DEA scheduling, but capabilities in the fields of pharmacology and medicinal chemistry advanced significantly during this “dark age.”

Marketing 235